Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 134, Issue 8, Pages 1705-1710Publisher
WILEY
DOI: 10.1038/sj.bjp.0704437
Keywords
MT-II; SHU 9119; cavernosal pressure; pudendal nerves; L-NAME; NO
Categories
Ask authors/readers for more resources
1 Melanotan-II had been reported to cause penile erections in men with erectile dysfunction. In the present study, we investigated the mechanisms by which systemic administration of MT-II increases intracavernosal pressure in anaesthetized rabbits. 2 MT-II (10 muM) had no effect on electrical field stimulation-evoked relaxations of rabbit corpus cavernosal strips in vitro. 3 Intravenous injection of MT-II (66 and 133 mug kg(-1) elicited dose-related increases in cavernosal pressure. SHU 9119 (3 mug kg(-1), i.v.), a non-selective antagonist of MC3 and MC4 receptors did not significantly affect either cavernosal pressure or systemic blood pressure but abolished the MT-II-induced increases in cavernosal pressure. SHU 9119 also inhibited the depressor response produced by MT-II. 4 Intracavernosal injection 100 mul of the cocktail containing phentolamine mesylate (1 mg ml(-1)), papaverine (20 mg ml(-1)) and PGE1 (20 mug ml(-1)) increased the cavernosal pressure by about 4 fold. 5 The role of NO-cyclic GMP dependent pathway to MT-II-induced increases in cavernosal pressure was investigated by bilateral transection of the pudendal nerves and by inhibition of NO synthase with L-NAME (20 mg kg(-1), i.v. over 30 min). Ablation of the pudendal nerves or pretreatment with L-NAME abolished the MT-II-induced increases in intracavernosal pressure in anaesthetized rabbits. 6 The data suggest that activation of central melanocortin receptors by MT-II increases cavernosal pressure by the neuronal release of NO.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available